---
title: "Soufflé Therapeutics Closes $135M Series B for RNA Delivery Beyond the Liver"
description: "Juvia Group led Soufflé Therapeutics' $135M Series B. The funding advances cell-targeted RNA medicines, where delivery and human data—not payload design alone—drive value."
date: 2026-10-15T02:14:00.000Z
source: https://venturecapitaltracker.com/souffle-therapeutics-135m-series-b-rna-delivery
---

# Soufflé Therapeutics Closes $135M Series B for RNA Delivery Beyond the Liver

> Juvia Group led Soufflé Therapeutics' $135M Series B. The funding advances cell-targeted RNA medicines, where delivery and human data—not payload design alone—drive value.

Soufflé Therapeutics has **closed a $135 million Series B**, led by Juvia Group. The October 13 announcement puts fresh capital behind a central problem in genetic medicine: getting an RNA drug into the right cells outside the liver.

The financing is confirmed, not a fundraising target. Valuation was not disclosed. The analytical question is whether a delivery platform can turn a promising mechanism into reproducible human results across several diseases.

## The transaction

| Field | Detail |
|---|---|
| Financing | $135 million, oversubscribed Series B |
| Lead | Juvia Group |
| New investors | TCGX, BB Biotech, Fidelity Management & Research, Balyasny and an unnamed sovereign wealth fund |
| Returning investors | Amgen Ventures, ARCH, Bessemer, Breyer, Invus, Janus Henderson, Leaps by Bayer, Polaris, Safar, TAS, Temasek and Vida |
| Status | Closed; announced October 13, 2026 |

## Delivery is the asset

Soufflé's REMEDY engine pairs cell-specific receptors with binders that carry oligonucleotide medicines into selected tissues. Its lead programs address FSHD, heart failure through the PLN target, and an undisclosed muscle/metabolic target. Proceeds support clinical studies and additional preclinical development.

This is not the same investment proposition as finding another RNA sequence. A drug can have a useful molecular target and still fail because too little reaches the intended tissue, the dose is poorly tolerated, or the effect does not last. A successful delivery method could support multiple products, but each new receptor, tissue and indication creates another validation burden.

That creates a platform-versus-pipeline tension. Investors benefit if one delivery insight transfers across programs; they lose that efficiency if every candidate requires a bespoke development process.

## Pharma validation is not equity funding

Bayer and Soufflé announced a separate heart-targeted siRNA collaboration in January. Such agreements can bring development expertise and commercial options, but they should not be combined with this Series B into a synthetic funding total.

Historical descriptions of Soufflé's capital also require care. Earlier reporting described just under $200 million across seed and Series A financing, rather than one precisely disclosed $200 million Series A. Potential collaboration milestones are neither cash already received nor venture equity.

## Where the competitive test lies

The relevant comparison is with other extrahepatic delivery approaches, including muscle-focused antibody-oligonucleotide platforms—not with software companies using AI to propose molecules. [Undecimal Bio's earlier-stage financing](/undecimal-bio-18m-seed-sirna-delivery) illustrates the same broader delivery problem, but does not imply equivalent technologies or clinical progress.

A compelling investor presentation would separate receptor targeting, actual cellular uptake, target knockdown, durability and functional outcomes. Evidence at one layer does not prove success at the next. Safety and manufacturing consistency must also hold at commercially useful doses.

These are VCT's analytical milestones, not claims that Soufflé has already met them.

## What would justify the next valuation step?

The strongest proof points would be human safety and pharmacodynamic data, evidence of durable activity in the intended tissue, and a credible manufacturing path. A second program that reproduces the delivery advantage would make the platform thesis substantially stronger than a single successful asset.

The Series B is large enough to fund meaningful tests. It does not remove clinical risk. For now, the funding story is best understood as institutional capital paying for the next evidence threshold in cell-selective RNA delivery.

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.